BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Myqorzo (Aficamten) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Myqorzo (Aficamten)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07600177-10786@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Myqorzo (Aficamten): Phase 4 readout est. (NCT07600177)
DESCRIPTION:Myqorzo (Aficamten)\, phase 4\, Hypertrophic Cardiomyopathy.\nS
 tudy: Mavacamten to Aficamten Transition in Patients With Obstructive Hype
 rtrophic Cardiomyopathy\nEstimated primary completion: 31 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/aficamten#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07600177
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848506-10786@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT04848506)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: Open-label Extension Study to Evaluate the Long-term Safety and To
 lerability of Aficamten in Adults With HCM\nEstimated primary completion: 
 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aficamten
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048
 48506
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412666-10786@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT06412666)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: A Study to Evaluate the Effect of Aficamten in Pediatric Patients 
 With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).\nEstimate
 d primary completion: January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/aficamten#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06412666
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
